6,286 reports of this reaction
2.2% of all NATALIZUMAB reports
#11 most reported adverse reaction
URINARY TRACT INFECTION is the #11 most commonly reported adverse reaction for NATALIZUMAB, manufactured by Biogen Inc.. There are 6,286 FDA adverse event reports linking NATALIZUMAB to URINARY TRACT INFECTION. This represents approximately 2.2% of all 289,050 adverse event reports for this drug.
NATALIZUMAB has an overall safety score of 75 out of 100. Patients taking NATALIZUMAB who experience urinary tract infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URINARY TRACT INFECTION is a less commonly reported adverse event for NATALIZUMAB, but still significant enough to appear in the safety profile.
In addition to urinary tract infection, the following adverse reactions have been reported for NATALIZUMAB:
The following drugs have also been linked to urinary tract infection in FDA adverse event reports:
URINARY TRACT INFECTION has been reported as an adverse event in 6,286 FDA reports for NATALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
URINARY TRACT INFECTION accounts for approximately 2.2% of all adverse event reports for NATALIZUMAB, making it a notable side effect.
If you experience urinary tract infection while taking NATALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.